Komrakova, Marina

[["dc.bibliographiccitation.firstpage","443"],["dc.bibliographiccitation.journal","Molecular Therapy - Nucleic Acids"],["dc.bibliographiccitation.lastpage","452"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Hoffmann, Daniel B."],["dc.contributor.author","Gruber, Jens"],["dc.contributor.author","Böker, Kai O."],["dc.contributor.author","Deppe, Delia"],["dc.contributor.author","Sehmisch, Stephan"],["dc.contributor.author","Schilling, Arndt F."],["dc.contributor.author","Lemus-Diaz, Nicolas"],["dc.contributor.author","Komrakova, Marina"],["dc.contributor.author","Schneider, Stefan"],["dc.date.accessioned","2019-07-09T11:45:51Z"],["dc.date.available","2019-07-09T11:45:51Z"],["dc.date.issued","2018"],["dc.description.abstract","Rebalancing of the RANKL/OPG system seems to be an effective treatment strategy in postmenopausal osteoporosis. Here, we evaluate the knockdown of RANKL by in-vivo-delivered siRNA in a rat model of osteoporosis. Virus-like-particles (VLPs) derived from polyoma JC virus were used for delivering RANKL siRNA in ovariectomized (OVX) rats. 48 rats were ovariectomized and treated with either 17β-estradiol (E2), VLPs containing RANKL siRNA (siRANKL), or VLPs containing non-cognate siRNA (siCtrl). All OVX groups were subdivided into the prophylaxis group (PG) and the therapy group (TG). The PG received treatment directly after being OVX for 10 weeks. The TG received treatment 5 weeks after being OVX for 5 weeks. Rats were sacrificed 10 weeks after being OVX. Bone and blood samples were analyzed. E2 and siRANKL showed a significant knockdown of RANKL mRNA. A protein knockdown was observed with E2 and siRANKL in the TG but not in the PG. No distinct improvements in biomechanical and morphological properties of the bones were observed after siRANKL treatment. In the PG, E2 protected the bone structure. We demonstrated successful mRNA and protein knockdown by VLP-mediated RNAi in vivo. Knockdown of membranous RANKL did not result in significant improvements of bone properties in this model of early-stage postmenopausal osteoporosis."],["dc.identifier.doi","10.1016/j.omtn.2018.06.001"],["dc.identifier.pmid","30195781"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15329"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59322"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2162-2531"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.subject.ddc","610"],["dc.title","Effects of RANKL Knockdown by Virus-like Particle-Mediated RNAi in a Rat Model of Osteoporosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Endocrinology"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Saul, Dominik"],["dc.contributor.author","Hohl, Friederike Eva"],["dc.contributor.author","Franz, Max Konrad"],["dc.contributor.author","Meyer, Ilka"],["dc.contributor.author","Taudien, Stefan"],["dc.contributor.author","Roch, Paul Jonathan"],["dc.contributor.author","Sehmisch, Stephan"],["dc.contributor.author","Komrakova, Marina"],["dc.date.accessioned","2021-08-12T07:45:42Z"],["dc.date.available","2021-08-12T07:45:42Z"],["dc.date.issued","2021"],["dc.description.abstract","Background In previous studies, we reported the beneficial impact of two lipoxygenase-inhibitors, Baicalein and Zileuton, on osteoporotic bone in a postmenopausal rat model. Whereas subcutaneous Baicalein predominantly improved cortical bone, Zileuton enhanced vertebral and femoral trabecular bone. In this study, we aimed to reveal whether the oral administration of Baicalein caused similar effects on bone and whether a combined administration of Baicalein and Zileuton could act synergistically to ameliorate the formerly reported effects in the musculoskeletal system. Methods We treated ovariectomized (OVX) female Sprague-Dawley rats either with Baicalein (10mg/kg BW), Zileuton (10mg/kg BW) or a combination of both (each 10mg/kg BW) for 13 weeks and compared with untreated OVX and NON-OVX groups (n=12-16 rats per group). Lumbar vertebral bodies and femora were analyzed. Tibiae were osteotomized, plate-stabilized (at week 8 after OVX) and likewise analyzed by biomechanical, histological, micro-computed tomographical and ashing tests. The skeletal muscle structure was analyzed. Results Oral administration of Baicalein did not confirm the reported favorable cortical effects in neither vertebra nor femur. Zileuton showed a beneficial effect on trabecular vertebra, while the femur was negatively affected. Callus formation was enhanced by all treatments; however, its density and biomechanical properties were unaltered. Lipoxygenase inhibition did not show a beneficial effect on skeletal muscle. The combination therapy did not ameliorate OVX-induced osteoporosis but induced even more bone loss. Conclusions The preventive anti-osteoporotic treatments with two lipoxygenase inhibitors applied either alone or in combination showed no benefit for the musculoskeletal system in estrogen deficient rats."],["dc.description.abstract","Background In previous studies, we reported the beneficial impact of two lipoxygenase-inhibitors, Baicalein and Zileuton, on osteoporotic bone in a postmenopausal rat model. Whereas subcutaneous Baicalein predominantly improved cortical bone, Zileuton enhanced vertebral and femoral trabecular bone. In this study, we aimed to reveal whether the oral administration of Baicalein caused similar effects on bone and whether a combined administration of Baicalein and Zileuton could act synergistically to ameliorate the formerly reported effects in the musculoskeletal system. Methods We treated ovariectomized (OVX) female Sprague-Dawley rats either with Baicalein (10mg/kg BW), Zileuton (10mg/kg BW) or a combination of both (each 10mg/kg BW) for 13 weeks and compared with untreated OVX and NON-OVX groups (n=12-16 rats per group). Lumbar vertebral bodies and femora were analyzed. Tibiae were osteotomized, plate-stabilized (at week 8 after OVX) and likewise analyzed by biomechanical, histological, micro-computed tomographical and ashing tests. The skeletal muscle structure was analyzed. Results Oral administration of Baicalein did not confirm the reported favorable cortical effects in neither vertebra nor femur. Zileuton showed a beneficial effect on trabecular vertebra, while the femur was negatively affected. Callus formation was enhanced by all treatments; however, its density and biomechanical properties were unaltered. Lipoxygenase inhibition did not show a beneficial effect on skeletal muscle. The combination therapy did not ameliorate OVX-induced osteoporosis but induced even more bone loss. Conclusions The preventive anti-osteoporotic treatments with two lipoxygenase inhibitors applied either alone or in combination showed no benefit for the musculoskeletal system in estrogen deficient rats."],["dc.identifier.doi","10.3389/fendo.2021.706504"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/88533"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-448"],["dc.publisher","Frontiers Media S.A."],["dc.relation.eissn","1664-2392"],["dc.rights","http://creativecommons.org/licenses/by/4.0/"],["dc.title","Inhibition of Lipoxygenases Showed No Benefit for the Musculoskeletal System in Estrogen Deficient Rats"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","6893137"],["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Journal of Nutrition and Metabolism"],["dc.bibliographiccitation.lastpage","9"],["dc.bibliographiccitation.volume","2016"],["dc.contributor.author","Hoffmann, Daniel B."],["dc.contributor.author","Griesel, Markus H."],["dc.contributor.author","Brockhusen, Bastian"],["dc.contributor.author","Tezval, Mohammad"],["dc.contributor.author","Komrakova, Marina"],["dc.contributor.author","Menger, Bjoern"],["dc.contributor.author","Wassmann, Marco"],["dc.contributor.author","Stuermer, Klaus Michael"],["dc.contributor.author","Sehmisch, Stephan"],["dc.date.accessioned","2019-07-09T11:42:06Z"],["dc.date.available","2019-07-09T11:42:06Z"],["dc.date.issued","2016"],["dc.description.abstract","Background. 8-Prenylnaringenin (8-PN) is the phytoestrogen with the highest affinity for estrogen receptor-𝛼� (ER-𝛼�), which is required to maintain BMD. The osteoprotective properties of 8-PN have been demonstrated previously in tibiae. We used a rat osteopenia model to perform the first investigation of 8-PN with whole-body vertical vibration (WBVV). Study Design. Ovariectomy was performed on 52 of 64 Sprague-Dawley rats. Five weeks after ovariectomy, one group received daily injections (sc) of 8-PN (1.77mg/kg) for 10 weeks; a second group was treated with both 8-PN and WBVV (twice a day, 15 min, 35Hz, amplitude 0.47 mm). Other groups received either onlyWBVV or no treatment. Methods.The rats were sacrificed 15 weeks after ovariectomy. Lumbar vertebrae and femora were removed for biomechanical and morphological assessment. Results. 8-PN at a cancer-safe dose did not cause fundamental improvements in osteoporotic bones. Treatmentwith 8-PN caused a slight increase in uterine wetweight. Combined therapy using WBVV and 8-PN showed no significant improvements in bone structure and biomechanical properties. Conclusion. We cannot confirm the osteoprotective effects of 8-PN at a cancer-safe dose in primary affected osteoporotic bones. Higher concentrations of 8-PN are not advisable for safety reasons. Adjunctive therapy with WBVV demonstrates no convincing effects on bones."],["dc.identifier.doi","10.1155/2016/6893137"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12873"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58593"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2090-0732"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Effects of 8-Prenylnaringenin and Whole-Body Vibration Therapy on a Rat Model of Osteopenia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","4"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Nutrition & Metabolism"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Saul, Dominik"],["dc.contributor.author","Weber, Marie"],["dc.contributor.author","Zimmermann, Marc Hendrik"],["dc.contributor.author","Kosinsky, Robyn Laura"],["dc.contributor.author","Hoffmann, Daniel Bernd"],["dc.contributor.author","Menger, Björn"],["dc.contributor.author","Taudien, Stefan"],["dc.contributor.author","Lehmann, Wolfgang"],["dc.contributor.author","Komrakova, Marina"],["dc.contributor.author","Sehmisch, Stephan"],["dc.date.accessioned","2019-07-09T11:49:50Z"],["dc.date.accessioned","2020-06-09T07:03:29Z"],["dc.date.available","2019-07-09T11:49:50Z"],["dc.date.available","2020-06-09T07:03:29Z"],["dc.date.issued","2019"],["dc.description.abstract","Background Osteoporosis is one of the world’s major medical burdens in the twenty-first century. Pharmaceutical intervention currently focusses on decelerating bone loss, but phytochemicals such as baicalein, which is a lipoxygenase inhibitor, may rescue bone loss. Studies evaluating the effect of baicalein in vivo are rare. Methods We administered baicalein to sixty-one three-month-old female Sprague-Dawley rats. They were divided into five groups, four of which were ovariectomized (OVX) and one non-ovariectomized (NON-OVX). Eight weeks after ovariectomy, bilateral tibial osteotomy with plate osteosynthesis was performed and bone formation quantified. Baicalein was administered subcutaneously using three doses (C1: 1 mg/kg BW; C2: 10 mg/kg BW; and C3: 100 mg/kg BW) eight weeks after ovariectomy for four weeks. Finally, femora and tibiae were collected. Biomechanical tests, micro-CT, ashing, histological and gene expression analyses were performed. Results Biomechanical properties were unchanged in tibiae and reduced in femora. In tibiae, C1 treatment enhanced callus density and cortical width and decreased callus area. In the C3 group, callus formation was reduced during the first 3 weeks after osteotomy, correlating to a higher mRNA expression of Osteocalcin, Tartrate-resistant acid phosphatase and Rankl. In femora, baicalein treatments did not alter bone parameters. Conclusions Baicalein enhanced callus density and cortical width but impaired early callus formation in tibiae. In femora, it diminished the biomechanical properties and calcium-to-phosphate ratio. Thus, it is not advisable to apply baicalein to treat early bone fractures. To determine the exact effects on bone healing, further studies in which baicalein treatments are started at different stages of healing are needed."],["dc.identifier.doi","10.1186/s12986-018-0327-2"],["dc.identifier.pmid","30651746"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15789"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59640"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66212"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1743-7075"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Effect of the Lipoxygenase Inhibitor Baicalein on Bone Tissue and Bone Healing in Ovariectomized Rats"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","100224"],["dc.bibliographiccitation.journal","Bone Reports"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Komrakova, M."],["dc.contributor.author","Rechholtz, C."],["dc.contributor.author","Pohlmann, N."],["dc.contributor.author","Lehmann, W."],["dc.contributor.author","Schilling, A. F."],["dc.contributor.author","Wigger, R."],["dc.contributor.author","Sehmisch, S."],["dc.contributor.author","Hoffmann, D. B."],["dc.date.accessioned","2019-09-24T08:05:04Z"],["dc.date.available","2019-09-24T08:05:04Z"],["dc.date.issued","2019"],["dc.description.abstract","Bisphosphonate alendronate (ALN), phytoestrogen 8-prenylnaringenin (8-PN) and the whole body vibration exert a favorable effect on osteoporotic bone. However, the impact of these treatments and the combination of pharmacological therapies with biomechanical stimulation on muscle and bone has not yet been explored in detail. The effect of ALN and 8-PN and their combination with the vibration (Vib) on skeletal muscle and bone healing was investigated in ovariectomized (Ovx) rats. Three-month old rats were Ovx (n = 78), or left intact (Non-Ovx; n = 12). Five weeks after Ovx, all rats were treated according to the group assignment (n = 12/13): 1) Non-Ovx; 2) Ovx; 3) Ovx + Vib; 4) Ovx + ALN; 5) Ovx + ALN + Vib; 6): Ovx + 8-PN; 7) Ovx + 8-PN + Vib. Treatments with ALN (0.58 mg/kg BW, in food), 8-PN (1.77 mg/kg BW, daily s.c. injections) and/or with vertical vibration (0.5 mm, 35 Hz, 1 g, 15 min, 2×/day, 5×/week) were conducted for ten weeks. Nine weeks after Ovx, all rats underwent bilateral tibia osteotomy with plate osteosynthesis and were sacrificed six weeks later. Vibration increased fiber size and capillary density in muscle, enlarged callus area and width, and decreased callus density in tibia, and elevated alkaline phosphatase in serum. ALN and ALN + Vib enhanced capillarization and lactate dehydrogenase activity in muscle. In tibia, ALN slowed bone healing, ALN + Vib increased callus width and density, enhanced callus formation rate and expression of osteogenic genes. 8-PN and 8-PN + Vib decreased fiber size and increased capillary density in muscle; callus density and cortical width were reduced in tibia. Vibration worsened 8-PN effect on bone healing decreasing the callus width and area. Our data suggest that Vib, ALN, 8-PN, or 8-PN + Vib do not appear to aid bone healing. ALN + Vib improved bone healing; however application is questionable since single treatments impaired bone healing. Muscle responds to the anti-osteoporosis treatments and should be included in the evaluation of the drugs."],["dc.identifier.doi","10.1016/j.bonr.2019.100224"],["dc.identifier.pmid","31516917"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16393"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/62450"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2352-1872"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.title","Effect of alendronate or 8-prenylnaringenin applied as a single therapy or in combination with vibration on muscle structure and bone healing in ovariectomized rats"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","168"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Calcified Tissue International"],["dc.bibliographiccitation.lastpage","180"],["dc.bibliographiccitation.volume","87"],["dc.contributor.author","Stuermer, Ewa Klara"],["dc.contributor.author","Komrakova, Marina"],["dc.contributor.author","Werner, Carsten"],["dc.contributor.author","Wicke, Michael"],["dc.contributor.author","Kolios, Leila"],["dc.contributor.author","Sehmisch, Stephan"],["dc.contributor.author","Tezval, Mohammad"],["dc.contributor.author","Utesch, Clara"],["dc.contributor.author","Mangal, Orzala"],["dc.contributor.author","Zimmer, Sebastian"],["dc.contributor.author","Dullin, Christian"],["dc.contributor.author","Stuermer, Klaus-Michael"],["dc.date.accessioned","2018-11-07T08:40:40Z"],["dc.date.available","2018-11-07T08:40:40Z"],["dc.date.issued","2010"],["dc.description.abstract","This study investigated the effect of vibration on bone healing and muscle in intact and ovariectomized rats. Thirty ovariectomized (at 3 months of age) and 30 intact 5-month old female Sprague-Dawley rats underwent bilateral metaphyseal osteotomy of tibia. Five days later, half of the ovariectomized and of the intact rats were exposed to whole-body vertical vibration (90 Hz, 0.5 mm, 4 x g acceleration) for 15 min twice a day during 30 days. The other animals did not undergo vibration. After decapitation of rats, one tibia was used for computed tomographic, biomechanical, and histological analyses; the other was used for gene expression analyses of alkaline phosphatase (Alp), osteocalcin (Oc), tartrate-resistant acid phosphatase 1, and insulinlike growth factor 1. Serum Alp and Oc were measured. Mitochondrial activity, fiber area and distribution, and capillary densities were analyzed in M. gastrocnemius and M. longissimus. We found that vibration had no effect on body weight and food intake, but it improved cortical and callus densities (97 vs. 99%, 72 vs. 81%), trabecular structure (9 vs. 14 trabecular nodes), blood supply (1.7 vs. 2.1 capillaries/fiber), and oxidative metabolism (17 vs. 23 pmol O(2)/s/mg) in ovariectomized rats. Vibration generally increased muscle fiber size. Tibia biomechanical properties were diminished after vibration. Oc gene expression was higher in vibrated rats. Serum Alp was increased in ovariectomized rats. In ovariectomized rats, vibration resulted in an earlier bridging; in intact rats, callus bridging occurred later after vibration. The chosen vibration regimen (90 Hz, 0.5 mm, 4 x g acceleration, 15 min twice a day) was effective in improving musculoskeletal tissues in ovariectomized rats but was not optimal for fracture healing."],["dc.description.sponsorship","German Research Foundation (DFG) [STU 478/3-1]"],["dc.identifier.doi","10.1007/s00223-010-9381-0"],["dc.identifier.isi","000280062200008"],["dc.identifier.pmid","20532877"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/4972"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19283"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0171-967X"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Musculoskeletal Response to Whole-Body Vibration During Fracture Healing in Intact and Ovariectomized Rats"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","20"],["dc.bibliographiccitation.journal","The Open Bone Journal"],["dc.bibliographiccitation.lastpage","26"],["dc.bibliographiccitation.volume","4"],["dc.contributor.author","Komrakova, Marina"],["dc.contributor.author","Stuermer, Ewa K."],["dc.contributor.author","Sturm, Armin"],["dc.contributor.author","Schmelz, Ulrich"],["dc.contributor.author","Tezval, Mohammad"],["dc.contributor.author","Stuermer, Klaus M."],["dc.contributor.author","Sehmisch, Stephan"],["dc.date.accessioned","2019-07-09T11:53:38Z"],["dc.date.available","2019-07-09T11:53:38Z"],["dc.date.issued","2012"],["dc.description.abstract","Daily application of parathyroid hormone (PTH 1-34) is used for treatment of osteoporosis. It was investigated whether orchiectomy-induced osteoporotic changes in spine can be ameliorated by every 48h administration of PTH in aged male rats. Eight-month-old male Sprague-Dawley rats were sham operated (n=24) or orchiectomized (Orx, n=36) and maintained untreated over 12 weeks. Thereafter, both tibia underwent transverse metaphyseal osteotomy (Komrakova et al. 2011, J Endocrinol; 209:9-19) and rats were divided into 5 groups treated s.c. as follows: 1) sham vehicle; 2) sham PTH every 24h (PTH/24h); 3) Orx vehicle; 4) Orx PTH/24h; 5) Orx PTH every 48h (PTH/48h). PTH dosage was 40 􀀁g/kg BW per injection. After 5 weeks, lumbar vertebral bodies were used in computed tomographical, biomechanical, histomorphological, ashing and gene expression analyses. Cortical and trabecular densities, biomechanical properties, serum osteocalcin level increased significantly after PTH treatments in all groups (yield load, sham: 232+17N, sham PTH/24h: 376+12N, Orx: 239+16N, Orx PTH/24h: 324+31N, Orx PTH/48h: 297+17N). Bone inorganic weight enhanced after daily PTH application in Orx rats. Bone gene expression did not differ (P>0.05) among the groups. Both PTH administration regimes (24h and 48h) improved impaired bone structure in osteopenic rats. Every 48h application was less effective, however, it improved bone properties to the level observed in healthy (sham) rats. Considering limitation of daily treatments known in humans, these results may be useful for further clinical studies."],["dc.identifier.doi","10.2174/1876525401204010020"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7843"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60468"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1876-5254"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Efficiency of 48h vs. 24h Injection of Parathyroid Hormone for Amelioration of Osteopenic Spine Properties in Male Rats"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Molecular Therapy — Nucleic Acids"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Hoffmann, Daniel B."],["dc.contributor.author","Boeker, Kai O."],["dc.contributor.author","Schneider, Stefan"],["dc.contributor.author","Eckermann-Felkl, Ellen"],["dc.contributor.author","Schuder, Angelina"],["dc.contributor.author","Komrakova, Marina"],["dc.contributor.author","Sehmisch, Stephan"],["dc.contributor.author","Gruber, Jens"],["dc.date.accessioned","2018-11-07T10:16:44Z"],["dc.date.available","2018-11-07T10:16:44Z"],["dc.date.issued","2016"],["dc.description.abstract","Bone remodeling requires a precise balance between formation and resorption. This complex process involves numerous factors that orchestrate a multitude of biochemical events. Among these factors are hormones, growth factors, vitamins, cytokines, and, most notably, osteoprotegerin (OPG) and the receptor activator for nuclear factor-kappaB ligand (RANKL). Inflammatory cytokines play a major role in shifting the RANKL/OPG balance toward excessive RANKL, resulting in osteoclastogenesis, which in turn initiates bone resorption, which is frequently associated with osteoporosis. Rebalancing RANKL/OPG levels may be achieved through either upregulation of OPG or through transient silencing of RANKL by means of RNA interference. Here, we describe the utilization of a viral capsid-based delivery system for in vivo and in vitro RNAi using synthetic small interfering RNA (siRNA) molecules in rat osteoblasts. Polyoma JC virus-derived virus-like particles are capable of delivering siRNAs to target RANKL in osteoblast cells both in vitro and in a rat in vivo system. Expression levels were monitored using quantitative real-time polymerase reaction and enzyme-linked immunosorbent assay after single and repeated injections over a 14-day period. Our data indicate that this is an efficient and safe route for in vivo delivery of gene modulatory tools to study important molecular factors in a rat osteoporosis model."],["dc.description.sponsorship","Elsbeth-Bonhoff Foundation [70]; Leibniz Association"],["dc.identifier.doi","10.1038/mtna.2016.15"],["dc.identifier.isi","000374465400003"],["dc.identifier.pmid","27003757"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13317"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41092"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","2162-2531"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.title","In Vivo siRNA Delivery Using JC Virus-like Particles Decreases the Expression of RANKL in Rats"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","400"],["dc.bibliographiccitation.journal","Frontiers in Endocrinology"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Saul, Dominik"],["dc.contributor.author","Geisberg, Laura Katharina"],["dc.contributor.author","Gehle, Torben"],["dc.contributor.author","Hoffmann, Daniel Bernd"],["dc.contributor.author","Tezval, Mohammad"],["dc.contributor.author","Sehmisch, Stephan"],["dc.contributor.author","Komrakova, Marina"],["dc.date.accessioned","2019-07-16T08:32:27Z"],["dc.date.accessioned","2020-06-10T14:24:58Z"],["dc.date.available","2019-07-16T08:32:27Z"],["dc.date.available","2020-06-10T14:24:58Z"],["dc.date.issued","2019"],["dc.description.abstract","Objective: In aging population, postmenopausal osteoporosis and decline of musculoskeletal function, referred to as \"frailty syndrome\" lead to loss of bone and muscle, causing falls, and fall-related injuries. To limit the impact of this portentous duo, simultaneous treatment of both is needed. Urocortin (UCN) has been reported to improve osteoporotic bone properties while its effect on muscle has not been addressed yet. Design and Methods: We aimed to investigate the effect of urocortin in vivo on skeletal muscle structure in osteopenic rats. Sixty Sprague-Dawley rats were divided into five groups: four were ovariectomized (OVX) and one underwent sham operation (SHAM). One ovariectomized group was left untreated (OVX), while one was treated with urocortin s.c. in 3 μg/kg body weight (bw) (OVX+UCN low), one with 30 μg/kg (OVX+UCN high), while one group was treated with estradiol orally (OVX+E: 0.2 mg/kg bw), each for 35 days. Mm. gastrocnemius, longissimus, and soleus were isolated and capillary density as well as diameters of type I and II fibers were measured. In addition, we examined the effect of UCN on tibia using biomechanical, micro-CT and ashing analysis and investigated the blood serum. Results: We demonstrated a positive effect of UCN on M. soleus, in which fiber diameter was positively influenced. The biomechanical and structural parameters of bone were not changed in UCN treated rats. The higher cholesterol, glucose and triglyceride levels in the \"UCN high\" group raise concern about this treatment. Conclusions: Our results portray urocortin as a substance that can be assessed for future therapeutic treatments of estrogen deficiency. New and Noteworthy: Urocortin has a positive effect on M. soleus (diameter). Urocortin raises serum cholesterol and triglyceride levels. Bone tissue was not affected by UCN."],["dc.identifier.doi","10.3389/fendo.2019.00400"],["dc.identifier.isi","WOS:000473058700001"],["dc.identifier.pmid","31293517"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16282"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/61553"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66223"],["dc.identifier.url","https://publons.com/publon/28102255/"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1664-2392"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Changes in Musculoskeletal System and Metabolism in Osteoporotic Rats Treated With Urocortin"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","100234"],["dc.bibliographiccitation.journal","Bone Reports"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Hoffmann, Daniel Bernd"],["dc.contributor.author","Popescu, Christian"],["dc.contributor.author","Komrakova, Marina"],["dc.contributor.author","Welte, Lena"],["dc.contributor.author","Saul, Dominik"],["dc.contributor.author","Lehmann, Wolfgang"],["dc.contributor.author","Hawellek, Thelonius"],["dc.contributor.author","Beil, Frank Timo"],["dc.contributor.author","Dakna, Mohammed"],["dc.contributor.author","Sehmisch, Stephan"],["dc.date.accessioned","2020-06-15T14:01:09Z"],["dc.date.available","2020-06-15T14:01:09Z"],["dc.date.issued","2020"],["dc.description.abstract","Introduction We evaluated the prevalence and influence of chronic hyponatremia in patients with low energy trauma. We also investigated the influence of medication and diseases on hyponatremia. Material and methods This retrospective study included 314 cases of proximal femoral fracture due to low energy trauma. Patients were treated in the University Medical Center Goettingen within 3 years. Hyponatremia was defined as serum sodium <135 mmol/L at admission. Results Overall, 15.6% of patients in the low energy trauma group had hyponatremia. Among patients older than 80 years, women showed distinctly higher rates of hyponatremia (female: 16.4%; male: 5.9%). In contrast only 4.7% of patients who underwent elective hip arthroplasty showed hyponatremia. Patients on sartanes and aldosterone antagonists showed significantly higher rates of hyponatremia. Alcoholism was significantly associated with hyponatremia. Conclusions We confirmed a high prevalence of chronic hyponatremia in patients with fractures due to low energy trauma. Our data underscore chronic hyponatremia as a contributing factor to hip fractures. Women older than 80 have a higher risk of developing hyponatremia. Sartanes, aldosterone antagonists, and alcohol disease are associated with hyponatremia. Treating hyponatremia may decrease the risk of fracture after low energy trauma. Therefore, physicians of different specialties should focus on treatment of chronic hyponatremia to reduce the fracture rate associated with low energy trauma."],["dc.identifier.doi","10.1016/j.bonr.2019.100234"],["dc.identifier.pmid","31909095"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17137"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66267"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2352-1872"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.title","Chronic hyponatremia in patients with proximal femoral fractures after low energy trauma: A retrospective study in a level-1 trauma center"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]